Nkarta (NKTX) announced the appointment of Shawn Rose as its next Chief Medical Officer and Head of Research and Development starting on June 23. He replaces David Shook, who will be stepping down from the role to pursue other opportunities in the oncology space. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX: